The prevalence, characteristics, and clinical significance of abnormal albuminuria in patients with hypertension

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Murai, Shunsuke ^a   Tanaka, Satoru ^a   Dohi, Yasuaki ^a   Kimura, Genjiro ^b   Ohte, Nobuyuki ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b Asahi Rosai Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMINOID; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATININE;

ADULT; AGED; ALBUMINURIA; ARTICLE; BLOOD; BLOOD PRESSURE; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; HYPERTENSION; INFLAMMATION; KIDNEY FAILURE; MALE; METABOLISM; MIDDLE AGED; RISK FACTOR; URINE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINS; ALBUMINURIA; BIOLOGICAL MARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CREATININE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; INFLAMMATION; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; RENAL INSUFFICIENCY; RISK FACTORS; YOUNG ADULT;

EID: 84893122475     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep03884     Document Type: Article

References (38)

1. Kannel, W. B. Hypertension as a risk factor for cardiac events: epidemiologic results of long-term studies. J. Cardiovasc. Pharmacol. 21, S27-S37 (1993)
2. Chobanian, A. V. et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42, 1206-1252 (2003)
3. Ogihara, T. et al. Japanese Society of Hypertension Committee. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009) Hypertens. Res. 32, 3-107 (2009)
4. Hillege, H. L. et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106, 1777-1782 (2002)
5. Sarnak, M. J. et al. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108, 2154-2169 (2003)
6. Manjunath, G. et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J. Am. Coll. Cardiol. 41, 47-55 (2003)
7. Matsushita, K. et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375, 2073-2081 (2010)
8. Schrader, J. et al. MARPLE Study Group. Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study) J. Hypertens. 24, 541-548 (2006)
9. Ohmaru, N. et al. Distribution pattern of urine albumin creatinine ratio and the prevalence of high-normal levels in untreated asymptomatic non-diabetic hypertensive patients. Intern. Med. 50, 1621-1629 (2011)
10. Robles, N. R. et al. Prevalence of abnormal urinary albumin excretion in a population-based study in Spain: results from the HERMEX Study. Eur. J. Clin. Invest. 42, 1272-1277 (2012)
11. Singh, A. K. & Kari, J. A. Metabolic syndrome and chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 22, 198-203 (2013)
12. Kim, Y. S. et al. Prevalence of microalbuminuria and associated risk factors among adult Korean hypertensive patients in a primary care setting. Hypertens. Res. 36, 807-823 (2013)
13. Wachtell, K. et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann. Intern. Med. 139, 901-906 (2003)
14. Yokoyama, H., Aoki, T., Imahori,M. & Kuramitsu, M. Subclinical atherosclerosis is increased in type 2 diabetic patients with microalbuminuria evaluated by intima-media thickness and pulse wave velocity. Kidney Int. 66, 448-454 (2004)
15. Chico, A., Tomas, A. & Novials, A. Silent myocardial ischemia is associated with autonomic neuropathy and other cardiovascular risk factors in type 1 and type 2 diabetic subjects, especially in those with microalbuminuria. Endocrine 27, 213-217 (2005)
16. Arnlöv, J. et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 112, 969-975 (2005)
17. Ibsen, H. et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 45, 198-202 (2005)
18. Araki, S. et al. Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. Diabetes 56, 1727-1730 (2007)
19. Daviglus, M. L. et al. Relation of nutrient intake to microalbuminuria in nondiabetic middle-aged men and women: International Population Study on Macronutrients and Blood Pressure (INTERMAP) Am. J. Kidney Dis. 45, 256-266 (2005)
20. Konta, T. et al. Prevalence and risk factor analysis of microalbuminuria in Japanese general population: the Takahata study. Kidney Int. 70, 751-756 (2006)
21. Tanaka, S., Takase, H., Dohi, Y. & Kimura, G. The prevalence and characteristics of microalbuminuria in the general population: a cross-sectional study. BMC Res. Notes. 6, 256 (2013) [Epub ahead of print].
22. Mukoyama, M. et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J. Clin. Invest. 87, 1402-1412 (1991)
23. Hirata, Y. et al. Measurement of plasma brain natriuretic peptide level as a guide for cardiac overload. Cardiovasc. Res. 51, 585-591 (2001)
24. Mukoyama, M. et al. Human brain natriuretic peptide, a novel cardiac hormone. Lancet 335, 801-802 (1990)
25. Buckley, M. G. et al. Plasma concentrations and comparisons of brain and atrial natriuretic peptide in normal subjects and in patients with essential hypertension. J. Hum. Hypertens. 7, 245-250 (1993)
26. ORourke, M. F. & Safar, M. E. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension 46, 200-204 (2005)
27. Yano, Y. et al. Plasma brain natriuretic peptide levels in normotensive noninsulindependent diabetic patients with microalbuminuria. J. Clin. Endocrinol. Metab. 84, 2353-2356 (1999)
28. Nagai, T., Imamura, M., Inukai, T. & Mori, M. Brain natriuretic polypeptide in type 2 NIDDM patients with albuminuria. J. Med. 32, 169-180 (2001)
29. Pedrinelli, R. et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet. 344, 14-18 (1994)
30. Malik, A. R., Sultan, S., Turner, S. T. & Kullo, I. J. Urinary albumin excretion is associated with impaired flow- and nitroglycerin-mediated brachial artery dilatation in hypertensive adults. J. Hum. Hypertens. 21, 231-238 (2007)
31. Silva, A. M. et al. Microalbuminuria is associated with impaired arterial and venous endothelium-dependent vasodilation in patients with Type 2 diabetes. J. Endocrinol. Invest. 33, 696-700 (2010)
32. Jiang, L. et al.Metabolic syndrome, C-reactive protein and microalbuminuria in a rural Chinese population: a cross-sectional study. BMC Nephrol. 14, 118 (2013) [Epub ahead of print].
33. Asselbergs, F. W. et al. Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 110, 2809-2816 (2004)
34. Bakris, G. L. et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int. 72, 879-885 (2007)
35. Glass, C. K. & Witztum, J. L. Atherosclerosis. the road ahead. Cell 104, 503-516 (2001)
36. Bianchi, S., Bigazzi, R., Caiazza, A. & Campese, V. M. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am. J. Kidney Dis. 41, 565-570 (2003)
37. Levey, A. S. et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 130, 461-470 (1999)
38. Matsuo, S. et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am. J. Kidney Dis. 53, 982-992 (2009)